Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall andKRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial

(2009) Heather-Jane Au et al.   JOURNAL OF CLINICAL ONCOLOGY

Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

(2009) Benjamin D. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials

(2008) Fairooz F. Kabbinavar et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials

(2007) Timothy R. Asmis et al.   JOURNAL OF CLINICAL ONCOLOGY